A Phase II Multicentric, Randomized, Double-blind, Placebo-controlled Study of TAR-0520 Gel in EGFR Inhibitor-induced Folliculitis.
Latest Information Update: 16 Feb 2025
At a glance
- Drugs TAR 0520 (Primary)
- Indications Folliculitis
- Focus Adverse reactions
- Sponsors Tarian Pharma
- 16 Feb 2025 New trial record